Processing your payment...
Please do not close your browser.

Alzheimer's Disease Drug Market- Global Growth, Trends and Forecast (2022 - 2029) By Type (Donepezil, Memantine, Rivastigmine) By Application (Early to Moderate Stages, Moderate to Severe Stages) and By Regions

12 Jul, 2022 | 134 Pages
Shares
facebook sharing button
linkedin sharing button
twitter sharing button
sharethis sharing button

Over the forecast period, the Alzheimer’s Disease Drug Market will register a CAGR of 3.1 % in terms of revenue and the global market size will reach USD 4.1 Billion by 2029.

Alzheimer’s Disease Drug Market Overview

Later in life, a steady loss of neurons does not significantly impair brain function throughout an average lifespan. However, the degree of neurologic impairment increases with age. Alzheimer's disease, also known as senile dementia, is characterized by excessive neuronal deterioration in maturity and is distinct from the natural aging processes. Memory loss, behavioral problems, and disruption of thought processes are all symptoms of Alzheimer's disease, a degenerative illness that kills brain cells. The condition is regarded as deadly. The two main risk factors for acquiring Alzheimer's disease are age and general heredity. These are risk factors as well, and they cannot be avoided. However, other reversible risk variables, like as environment, food, and general health, have been related to the emergence of AD.

According to estimates, 6% of those over 65 may have Alzheimer's disease. Because of improvements in sanitation, nutrition, medical research, and healthcare, life expectancy has been rising globally. As the population continues to live longer, this creates a situation where there will be more people with Alzheimer's disease in the future.

What is our Alzheimer’s Disease Drug Market report scope?

 

Report Attributes

 

 

Report Details

 

Forecast Period 2022 to 2029

 

CAGR of 3.1 % during the review period (2022 to 2029).

 

By Type

  • Donepezil
  • Memantine
  • Rivastigmine

 

By Applications

 

 

 

 

  • Early to Moderate Stages
  • Moderate to Severe Stages

 

 

 

By Companies

  • Allergan
  • Eisai
  • Novartis
  • Daiichi Sankyo
  • Merz Pharma
  • Pfizer
  • Johnson & Johnson
  • Lundbeck

 

 

 

Regions Covered

 

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

 

 

 

 

 

 

 

 

Countries Covered

  • US
  • Canada
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • Middle East & Africa
  • Latin America

Base Year

2022

 

Historical Year

 

 

2017 to 2021

Forecast Year

 

2022 to 2029

Number of Pages

134

 

Customization Available

 

 

Yes, the report can be customized as per your needs

Frequently Asked Questions

What are the current market size and compound annual growth rate (CAGR) of the Alzheimer’s Disease Drug Market during the forecast period (2022-2029)?

The Alzheimer’s Disease Drug Market is growing at a CAGR of 3.1 % over the next 7 years.

Who are the key players in Alzheimer’s Disease Drug Market?

Allergan, Eisai, Novartis, Daiichi Sankyo, Merz Pharma, Pfizer, Johnson & Johnson, Lundbeck, and Others.

What region does this Alzheimer’s Disease Drug Market report cover?

North America (the United States, Canada, and Mexico), Europe (Germany, France, UK, Russia, and Italy), Asia-Pacific (China, Japan, Korea, India, and Southeast Asia), South America (Brazil, Argentina, Colombia, etc.), The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

What is the significant Type of the Alzheimer’s Disease Drug Market?

Donepezil, Memantine, Rivastigmine.

What are the significant Applications of the Alzheimer’s Disease Drug Market?

Early to Moderate Stages, Moderate to Severe Stages.

Who are the Major Players in Alzheimer’s Disease Drug Market?

Market Growth Reports lists all the Alzheimer’s Disease Drug Market companies that are presently striving to reduce the impact of the Covid-19 pandemic on the Market- Allergan, Eisai, Novartis, Daiichi Sankyo, Merz Pharma, Pfizer, Johnson & Johnson, Lundbeck, Others

Industry News:

FDA Grants Accelerated Approval for Alzheimer’s Drug

On June 07, 2021, The U.S. Food and Drug Administration approved Aduhelm (aducanumab) for the treatment of Alzheimer’s, a debilitating disease affecting 6.2 million Americans. Aduhelm was approved using the accelerated approval pathway, which can be used for a drug for a serious or life-threatening illness that provides a meaningful therapeutic advantage over existing treatments. Accelerated approval can be based on the drug’s effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients, with a required post-approval trial to verify that the drug provides the expected clinical benefit.

What are the major Types and Applications of the Alzheimer’s Disease Drug Market?

By Type, it is segmented into

  • Donepezil
  • Memantine
  • Rivastigmine

By Applications, it is segmented into

  • Early to Moderate Stages
  • Moderate to Severe Stages

Alzheimer’s Disease Drug Market Regional Analysis

The market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa based on geography (MEA). The North American continent is further divided into nations like the United States and Canada. Europe is further divided into the United Kingdom, France, Germany, Italy, Spain, Russia, and the Rest of Europe. China, Japan, South Korea, India, Australia, South East Asia, and the rest of Asia Pacific make up the subregion of Asia Pacific. The MEA area is further split into the GCC, Turkey, South Africa, and the Rest of the MEA. The Latin America region is further divided into Brazil, Mexico, and the Rest of Latin America.

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Rest of the World
    • Middle East & Africa
    • Latin America
  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
  4. Key Insights
    1. Pricing Analysis, By Key Regions, 2022
    2. Price Comparison (USD Per Ton) By Type (Donepezil, Memantine, Rivastigmine) 2022
    3. Price Comparison (USD, Per Ton): By Application (Early to Moderate Stages, Moderate to Severe Stages) 2022
    4. Impact of COVID-19 on the Alzheimer’s Disease Drug Market
    5. Production Share of Alzheimer’s Disease Drug, By Region, 2022
    6. Key Industry Developments
  5. Global Alzheimer’s Disease Drug Market Analysis, Insights and Forecast, 2022-2029
    1. Market Analysis, Insights, and Forecast – By Type
      1. Donepezil
      2. Memantine
      3. Rivastigmine 
    2. Market Analysis, Insights, and Forecast – By Application
      1. Early to Moderate Stages
      2. Moderate to Severe Stages 
    3. Market Analysis, Insights, and Forecast – By Region
      1. North America
      2. Europe
      3. Asia Pacific
      4. Rest of World
  6. Competitive Analysis
    1. Global Market Share Analysis (2022)
    2. Company Profiles (Overview, Products, SWOT analysis, recent developments, strategies, financials (based on availability))
      1. Allergan
        1. Overview,
        2. Products,
        3. SWOT analysis,
        4. Recent developments,
        5. strategies,
        6. financials (based on availability)
      2. Eisai
        1. Overview,
        2. Products,
        3. SWOT analysis,
        4. Recent developments,
        5. strategies,
        6. financials (based on availability)
      3. Novartis
        1. Overview,
        2. Products,
        3. SWOT analysis,
        4. Recent developments,
        5. strategies,
        6. financials (based on availability)
      4. Daiichi Sankyo
        1. Overview,
        2. Products,
        3. SWOT analysis,
        4. Recent developments,
        5. strategies,
        6. financials (based on availability)

 

SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.

PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.

MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.

EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.

REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.

Request A Sample

Please Choose License Type

  • Single User License
    $2500
  • Site License
    $3000
  • Global License
    $5000

How can we help you?

Reach us with your research requirements and we shall provide the optimum solution to suit your needs.

Curioust about Multiple Reports?

Discounts available for multiple report purchases.

Contact Us

Our Clients

  • Korean Institute of Tuberculosis
  • Sanyo chemical Industries LTD
  • Novartis
  • Hisamitsu
  • Pfizer
  • AbbVie
  • RevHealth
  • Zeon Corporation
  • Abbott (Established Pharmaceutical Products)
  • Sinopharm (pharmaceutical distribution segment)
  • Takeda Pharmaceutical
  • Gilead Sciences
  • Sartorius
  • Zavation
  • Permobil
  • Ansell
  • Cefla